Header Logo

Connection

Co-Authors

Back to Details
This is a "connection" page, showing publications co-authored by AMAN U BUZDAR and VICENTE VALERO.
AMAN U BUZDAR
Connection Strength
0.848
VICENTE VALERO
  1. Phase III trial evaluating weekly paclitaxel versus docetaxel in combination with capecitabine in operable breast cancer. J Clin Oncol. 2012 Mar 20; 30(9):930-5.
    View in: PubMed
    Score: 0.103
  2. Primary chemotherapy in the treatment of breast cancer: the University of Texas M. D. Anderson Cancer Center experience. Clin Breast Cancer. 2002 Oct; 3 Suppl 2:S63-8.
    View in: PubMed
    Score: 0.054
  3. Molecular Characterization and Prospective Evaluation of Pathologic Response and Outcomes with Neoadjuvant Therapy in Metaplastic Triple-Negative Breast Cancer. Clin Cancer Res. 2022 07 01; 28(13):2878-2889.
    View in: PubMed
    Score: 0.053
  4. Prospective evaluation of paclitaxel versus combination chemotherapy with fluorouracil, doxorubicin, and cyclophosphamide as neoadjuvant therapy in patients with operable breast cancer. J Clin Oncol. 1999 Nov; 17(11):3412-7.
    View in: PubMed
    Score: 0.044
  5. Phase II trial of liposome-encapsulated doxorubicin, cyclophosphamide, and fluorouracil as first-line therapy in patients with metastatic breast cancer. J Clin Oncol. 1999 May; 17(5):1425-34.
    View in: PubMed
    Score: 0.042
  6. A phase II study of tipifarnib and gemcitabine in metastatic breast cancer. Invest New Drugs. 2018 04; 36(2):299-306.
    View in: PubMed
    Score: 0.039
  7. Long-Term Prognostic Risk After Neoadjuvant Chemotherapy Associated With Residual Cancer Burden and Breast Cancer Subtype. J Clin Oncol. 2017 Apr 01; 35(10):1049-1060.
    View in: PubMed
    Score: 0.036
  8. Phase II trial of docetaxel: a new, highly effective antineoplastic agent in the management of patients with anthracycline-resistant metastatic breast cancer. J Clin Oncol. 1995 Dec; 13(12):2886-94.
    View in: PubMed
    Score: 0.034
  9. Phase I clinical and pharmacological study of suppression of human antimouse antibody response to monoclonal antibody L6 by deoxyspergualin. Cancer Res. 1995 Jul 15; 55(14):3060-7.
    View in: PubMed
    Score: 0.033
  10. Locoregional recurrence risk for patients with T1,2 breast cancer with 1-3 positive lymph nodes treated with mastectomy and systemic treatment. Int J Radiat Oncol Biol Phys. 2014 Jun 01; 89(2):392-8.
    View in: PubMed
    Score: 0.030
  11. Bioequivalence of 20-mg once-daily tamoxifen relative to 10-mg twice-daily tamoxifen regimens for breast cancer. J Clin Oncol. 1994 Jan; 12(1):50-4.
    View in: PubMed
    Score: 0.029
  12. Short-term biomarker modulation prevention study of anastrozole in women at increased risk for second primary breast cancer. Cancer Prev Res (Phila). 2012 Feb; 5(2):276-82.
    View in: PubMed
    Score: 0.025
  13. Phase III randomized trial of dose intensive neoadjuvant chemotherapy with or without G-CSF in locally advanced breast cancer: long-term results. Oncologist. 2011; 16(11):1527-34.
    View in: PubMed
    Score: 0.025
  14. Efficacy of neoadjuvant therapy with trastuzumab concurrent with anthracycline- and nonanthracycline-based regimens for HER2-positive breast cancer. Cancer. 2012 May 01; 118(9):2385-93.
    View in: PubMed
    Score: 0.025
  15. Residual risk of breast cancer recurrence 5 years after adjuvant therapy. J Natl Cancer Inst. 2008 Aug 20; 100(16):1179-83.
    View in: PubMed
    Score: 0.020
  16. Clinical features associated with a favorable outcome following neoadjuvant chemotherapy in women with localized breast cancer aged 35 years or younger. J Cancer Res Clin Oncol. 2009 Jan; 135(1):141-8.
    View in: PubMed
    Score: 0.020
  17. Colitis in patients with breast carcinoma treated with taxane-based chemotherapy. Cancer. 2004 Oct 01; 101(7):1508-13.
    View in: PubMed
    Score: 0.015
  18. Surgical conservation planning after neoadjuvant chemotherapy for stage II and operable stage III breast carcinoma. Am J Surg. 2001 Dec; 182(6):601-8.
    View in: PubMed
    Score: 0.013
  19. Female patients with breast carcinoma age 30 years and younger have a poor prognosis: the M.D. Anderson Cancer Center experience. Cancer. 2001 Nov 15; 92(10):2523-8.
    View in: PubMed
    Score: 0.013
  20. Paclitaxel in the multimodality treatment for inflammatory breast carcinoma. Cancer. 2001 Oct 01; 92(7):1775-82.
    View in: PubMed
    Score: 0.013
  21. Factors predictive of outcome in patients with breast cancer refractory to neoadjuvant chemotherapy. Cancer J. 2001 Sep-Oct; 7(5):413-20.
    View in: PubMed
    Score: 0.012
  22. Phase I study of vinorelbine and paclitaxel by 3-hour simultaneous infusion with and without granulocyte colony-stimulating factor support in metastatic breast carcinoma. Cancer. 2001 Feb 15; 91(4):664-71.
    View in: PubMed
    Score: 0.012
  23. Long-term results of combined-modality therapy for locally advanced breast cancer with ipsilateral supraclavicular metastases: The University of Texas M.D. Anderson Cancer Center experience. J Clin Oncol. 2001 Feb 01; 19(3):628-33.
    View in: PubMed
    Score: 0.012
  24. Chemotherapy of metastatic breast cancer: what to expect in 2001 and beyond. Oncologist. 2001; 6(2):133-46.
    View in: PubMed
    Score: 0.012
  25. Phase I-II vinorelbine (Navelbine) by continuous infusion in patients with metastatic breast cancer: cumulative toxicities limit dose escalation. Cancer Invest. 2001; 19(5):459-66.
    View in: PubMed
    Score: 0.012
  26. Phase II study of paclitaxel in patients with metastatic breast carcinoma refractory to standard chemotherapy. Cancer. 2000 Dec 01; 89(11):2195-201.
    View in: PubMed
    Score: 0.012
  27. Phase I study of vinorelbine by 96-hour infusion in advanced metastatic breast cancer. Am J Clin Oncol. 2000 Apr; 23(2):117-21.
    View in: PubMed
    Score: 0.011
  28. Randomized trial of high-dose chemotherapy and blood cell autografts for high-risk primary breast carcinoma. J Natl Cancer Inst. 2000 Feb 02; 92(3):225-33.
    View in: PubMed
    Score: 0.011
  29. A unified definition of clinical anthracycline resistance breast cancer. Br J Cancer. 2000 Feb; 82(3):529-34.
    View in: PubMed
    Score: 0.011
  30. Colitis associated with docetaxel-based chemotherapy in patients with metastatic breast cancer. Lancet. 2000 Jan 22; 355(9200):281-3.
    View in: PubMed
    Score: 0.011
  31. Phase II study of vinorelbine administered by 96-hour infusion in patients with advanced breast carcinoma. Cancer. 1999 Oct 01; 86(7):1251-7.
    View in: PubMed
    Score: 0.011
  32. Paclitaxel by 24-hour infusion with doxorubicin by 48-hour infusion as initial therapy for metastatic breast cancer: phase I results. Ann Oncol. 1999 Apr; 10(4):403-11.
    View in: PubMed
    Score: 0.011
  33. Phase I/II trial of high dose mitoxantrone in metastatic breast cancer: the M.D. Anderson Cancer Center experience. Breast Cancer Res Treat. 1999 Apr; 54(3):225-33.
    View in: PubMed
    Score: 0.011
  34. Clinical course of breast cancer patients with metastases confined to the lungs treated with chemotherapy. The University of Texas M.D. Anderson Cancer Center experience and review of the literature. Ann Oncol. 1998 Apr; 9(4):413-8.
    View in: PubMed
    Score: 0.010
  35. Sequence-dependent alteration of doxorubicin pharmacokinetics by paclitaxel in a phase I study of paclitaxel and doxorubicin in patients with metastatic breast cancer. J Clin Oncol. 1996 Oct; 14(10):2713-21.
    View in: PubMed
    Score: 0.009
  36. Phase II study of deoxyspergualin in metastatic breast cancer. Invest New Drugs. 1994; 12(3):235-41.
    View in: PubMed
    Score: 0.007
  37. The M. D. Anderson Cancer Center experience with Taxol in metastatic breast cancer. J Natl Cancer Inst Monogr. 1993; (15):161-9.
    View in: PubMed
    Score: 0.007
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.